First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Amgen Inc.

    AMGN · 73 developments mapped · last assessed 2026-09-28

    Market Ontology has mapped 73 macro, policy, and market developments to Amgen Inc. since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for AMGN yet, so no modelled value is shown. The AMGN valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run AMGN on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for AMGN. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways

      Validation of novel therapeutic approaches, potential for future pipeline expansion or partnerships in cardiovascular diseases, especially given their existing cardiovascular portfolio.

      · Moves probability of success pipeline, addressable market size, r&d efficiency

    • Main threat

      Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage

      Intensified competition in the metabolic disease space, potentially diverting R&D focus and market attention from other therapeutic areas.

      · Moves pipeline success rates, market share projections, r&d efficiency

    • Open question

      Eli Lilly Immunology Revenue Reaches $2.6B in H1 2026 on Taltz and New Launches

      Competitive landscape in the immunology market. LLY's strong immunology growth, particularly with Taltz (psoriasis/psoriatic arthritis), could pose a competitive challenge to AMGN's immunology assets like Otezla and Enbrel.

      · Moves market share expectations, revenue growth rate

    What changed, by assumption

    Probability of success pipeline
    • 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    Pipeline success rates
    • 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in 1H 2026 as oral Foundayo expands PBM coverage
    • 2026-09-18Eli Lilly posts $27.7B 1H GLP-1 revenue as oral obesity drug Foundayo expands
    Future revenue growth from pipeline assets
    • 2026-09-18Eli Lilly GLP-1 revenue reaches $27.7B in H1 2026 as oral obesity drug expands coverage
    Probability of success for pipeline obesity drugs
    • 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial for Enicepatide
    Probability of success for pipeline assets (e.g., maridebart cafraglutide)
    • 2026-09-23Roche Reports 15.5% Weight Loss in Phase II Trial of Dual GLP-1/GIP Agonist Enicepatide

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-28Eli Lilly Discontinues Sub-Efficacy GLP-1 Drug Amid Pipeline R&D Reallocationwatch3-12m0.20
    2026-09-28Eli Lilly discontinues pipeline GLP-1 candidate following efficacy reviewBullish3-12m0.10
    2026-09-28HUTCHMED doses first patient in Phase Ia trial of KRAS-EGFR conjugate HMPL-A830watch1-5y0.20
    2026-09-28Eli Lilly drops pipeline GLP-1 candidate on efficacy while maintaining franchise leadmixed3-12m0.20
    2026-09-28Eli Lilly Discontinues Early-Stage GLP-1 Candidate Following Efficacy ReviewBullish1-3m0.10
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate as Core Incretin Portfolio Reaches 65% of SalesBullish3-12m0.30
    2026-09-28Eli Lilly Discontinues Sub-Par GLP-1 Candidate to Refocus Capital on Next-Gen Formulationsmixed3-12m0.30
    2026-09-28Eli Lilly Drops Experimental GLP-1 Candidate Following Subpar Efficacy DataBullish3-12m0.40
    2026-09-28HUTCHMED Initiates Phase Ia Global Trial of First-in-Class KRAS-EGFR Conjugatewatch1-5y0.20
    2026-09-27Eli Lilly Drops Experimental Obesity Candidate; Incretins Exceed 65% of Total RevenueBullish3-12m0.30
    2026-09-27Eli Lilly Drops Pipeline Obesity Asset as GLP-1 Franchise Exceeds 65% RevenueBullish1-5y0.30
    2026-09-27Eli Lilly discontinues developmental obesity drug over unmet efficacy thresholdwatch3-12m0.30